Corcept Therapeutics (FRA:HTD) Cash Flow from Investing: €-20.4 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HTD Corcept Therapeutics Inc FRA:HTD
85 GF Score
Price €100.70
GF Value €61.96
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Corcept Therapeutics Cash Flow from Investing?

Corcept Therapeutics FRA:HTD -3.06% 85 Cash Flow from Investing is €-20.4 Mil as of Jun. 2026. GuruFocus rates FRA:HTD with a GF Score™ of 85/100 and a GF Value™ of €61.96 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Jun. 2026, Corcept Therapeutics spent €2.2 Mil on purchasing property, plant, equipment. It gained € Mil from selling property, plant, and equipment. It spent €0.0 Mil on purchasing business. It gained €0.0 Mil from selling business. It spent €76.8 Mil on purchasing investments. It gained €53.8 Mil from selling investments. It paid €0.0Mil for net Intangibles purchase and sale. And it received €0.0 Mil from other investing activities. In all, Corcept Therapeutics spent €25.1 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Jun. 2026.


Corcept Therapeutics  (FRA:HTD) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Corcept Therapeutics's purchase of property, plant, equipment for the three months ended in Jun. 2026 was €-2.2 Mil. It means Corcept Therapeutics spent €2.2 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Corcept Therapeutics's sale of property, plant, equipment for the three months ended in Jun. 2026 was € Mil. It means Corcept Therapeutics gained € Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Corcept Therapeutics's purchase of business for the three months ended in Jun. 2026 was €0.0 Mil. It means Corcept Therapeutics spent €0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Corcept Therapeutics's sale of business for the three months ended in Jun. 2026 was €0.0 Mil. It means Corcept Therapeutics gained €0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Corcept Therapeutics's purchase of investment for the three months ended in Jun. 2026 was €-76.8 Mil. It means Corcept Therapeutics spent {stock_data.stock.currency_symbol}}76.8 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Corcept Therapeutics's sale of investment for the three months ended in Jun. 2026 was €53.8 Mil. It means Corcept Therapeutics gained €53.8 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Corcept Therapeutics's net Intangibles purchase and sale for the three months ended in Jun. 2026 was € Mil. It means Corcept Therapeutics paid €0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Corcept Therapeutics's cash from discontinued investing activities for the three months ended in Jun. 2026 was Mil. It means Corcept Therapeutics paid €0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Corcept Therapeutics's cash from other investing activities for the three months ended in Jun. 2026 was €0.0 Mil. It means Corcept Therapeutics received €0.0 Mil from other investing activities.


Corcept Therapeutics Cash Flow from Investing Related Terms


Corcept Therapeutics Cash Flow from Investing Historical Data

* Premium members only.

The historical data trend for Corcept Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Cash Flow from Investing Chart

Corcept Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 115.17 -108.78 84.09 -164.19 61.81

Corcept Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.09 10.75 -9.89 3.88 -25.13
FRA:HTD
85GF Score
Corcept Therapeutics Inc FRA:HTD
Cash Flow from Investing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corcept Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Corcept Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2025 is calculated as:

Corcept Therapeutics's Cash Flow from Investing for the quarter that ended in Jun. 2026 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-20.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Investing of €-20.4 Mil mean?
Corcept Therapeutics (FRA:HTD) has a Cash Flow from Investing of €-20.4 Mil as of Jun. 2026. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Corcept Therapeutics and its competitors.
Is Corcept Therapeutics' Cash Flow from Investing too high?
Corcept Therapeutics' current Cash Flow from Investing is €-20.4 Mil. Overall, Corcept Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Cash Flow from Investing compare to MDGL and BMRN?
Corcept Therapeutics' Cash Flow from Investing of €-20.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Investing for a Biotechnology company?
A good Cash Flow from Investing depends on the Biotechnology industry context. However, Cash Flow from Investing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Investing mean?
A high Cash Flow from Investing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Corcept Therapeutics and its competitors. Corcept Therapeutics's current Cash Flow from Investing is €-20.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (FRA:HTD) is currently considered Significantly Overvalued. The stock's GF Value™ is €61.96, compared to a current price of €100.70 — trading 62.5% above its estimated fair value. The current Cash Flow from Investing is €-20.4 Mil. Corcept Therapeutics' overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Investing calculated?
Cash Flow from Investing is calculated from a company's financial statements. For Corcept Therapeutics (FRA:HTD), the current Cash Flow from Investing is €-20.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (FRA:HTD) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of €100.70 is trading 62.5% above its estimated GF Value™ of €61.96. GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:HTD:

  • Cash Flow from Investing: €-20.4 Mil
  • GF Value™: €61.96 vs. price of €100.70 (62.5% above fair value)
  • GF Score™: 85/100 with 9 warning signs

No single metric tells the full story. See the FRA:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Corcept Therapeutics Business Description

Other Exchanges CORT:USA1CORT:Italy0I3Q:UK
Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score

Get the complete analysis for FRA:HTD

Cash Flow from Investing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€100.70
Price
€61.96
GF Value